e-learning
resources
ERJ
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Delivering high value therapies in COPD: the secret is in the marketing
Helen Ashdown, Michael Steiner
Source:
Eur Respir J, 53 (4) 1900215; 10.1183/13993003.00215-2019
Journal Issue:
April
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Helen Ashdown, Michael Steiner. Delivering high value therapies in COPD: the secret is in the marketing. Eur Respir J, 53 (4) 1900215; 10.1183/13993003.00215-2019
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Evidence-based eHealth for COPD
Related content which might interest you:
Maintaining currency and improving utility of COPD guidelines: an achievable goal?
Source: Annual Congress 2009 - Quality of treatment in primary respiratory care
Year: 2009
Aiming for total control in asthma: an ineffective use of resources?
Source: Eur Respir J 2005; 26: Suppl. 49, 429s
Year: 2005
The sustainability agenda and inhaled therapy: what do patients want?
Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence
Year: 2021
The concept of control in COPD: a new proposal for optimising therapy
Source: Eur Respir J 2014; 44: 1072-1075
Year: 2014
Prescription opioid use in advanced COPD: benefits, perils and controversies
Source: Eur Respir J, 49 (6) 1700479; 10.1183/13993003.00479-2017
Year: 2017
Prescription opioid use in advanced COPD: benefits, perils and controversies
Source: Eur Respir J, 49 (6) 1700690; 10.1183/13993003.00690-2017
Year: 2017
A lifeline for COPD: prevention strategy
Source: Breathe 2010; 6: 204-209
Year: 2010
Optimising COPD prevention: what do the doctors need?
Source: Annual Congress 2007 - Smoking and the lung
Year: 2007
Getting approval for new therapeutic medical devices versus drugs: are the differences justified?
Source: Eur Respir Rev 2016; 25: 223-226
Year: 2016
COPD self management: The impact of implementing self management plans & rescue medications across 3 hospitals
Source: Annual Congress 2012 - Pharmacological and non-pharmacological management of COPD
Year: 2012
Tele-education in asthma management. What are the benefits?
Source: Annual Congress 2012 - Improving education for the healthcare team and patients
Year: 2012
Adding biological markers to COPD categorisation schemes: a way towards more personalised care?
Source: Eur Respir J 2016; 47:1601-1605
Year: 2016
Respiratory medicines for children: current evidence, unlicensed use and research priorities
Source: Eur Respir J 2010; 35: 247-265
Year: 2010
Getting the rehabilitation message across: emerging barriers and positive health benefits
Source: Eur Respir J 2009; 34: 2-4
Year: 2009
Pros: governments should impose targets for healthcare professionals to switch their respiratory disease patients to inhalers with a low global warming potential
Source: International Congress 2019 – Recent clinical advances in inhalation therapy
Year: 2019
Realising the potential of mHealth to improve asthma and allergy care: how to shape the future
Source: Eur Respir J, 49 (5) 1700447; 10.1183/13993003.00447-2017
Year: 2017
Doctors‘ compliance and adherence to treatment standards for asthma in Ukraine: who needs it more?
Source: Eur Respir J 2005; 26: Suppl. 49, 381s
Year: 2005
Cons - governments should impose targets for healthcare professionals to switch their respiratory disease patients to inhalers with a low global warming potential
Source: International Congress 2019 – Recent clinical advances in inhalation therapy
Year: 2019
Tuberculosis elimination, patients' lives and rational use of new drugs: revisited
Source: Eur Respir J 2016; 47: 664-667
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept